Compare HRTX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRTX | MBOT |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 145.7M |
| IPO Year | 2007 | 2000 |
| Metric | HRTX | MBOT |
|---|---|---|
| Price | $0.78 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 2.1M | 1.6M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $116,887.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $4,200.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.75 | $1.35 |
| 52 Week High | $2.61 | $4.62 |
| Indicator | HRTX | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 25.53 | 55.13 |
| Support Level | N/A | $2.34 |
| Resistance Level | $1.41 | $2.60 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 9.41 | 41.46 |
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.